Phase 1b data readout in Q3 2026 is the next major catalyst. Monitor for safety/tolerability and pharmacokinetic results that could de-risk the Phase 2 program. No financial guidance or commercial timeline provided.
MNKD drugs
MNKD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $3.36entry
- T+1 · 6mo ago +4.76%α +4.36% · $3.52
- T+5 · 5mo ago +8.04%α +11.86% · $3.63
- T+20 · 5mo ago +34.52%α +35.52% · $4.52
- T+60 · 3mo ago +20.83%α +18.33% · $4.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first patient in the global Phase 2 INFLO-2 study for nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis. Phase 1b data readout is expected in Q3 2026, representing a key clinical milestone for the program.
Key Facts
- Phase 1b INFLO-1 patient randomization completed; data readout expected Q3 2026
- First patient enrolled in global Phase 2 INFLO-2 study (target ~210 participants across ~85 sites)
- Nintedanib DPI (MNKD-201) uses Technosphere dry powder inhalation technology to deliver drug directly to lungs
- INFLO-2 is a randomized, double-blind, placebo-controlled trial with 12-week treatment period and 24-week open-label extension
- Primary objective of INFLO-2 is safety and tolerability; secondary includes FVC decline rate
Financial Impact
No financial data provided; program is in early clinical development with no revenue contribution expected near-term
Risk Factors
- Clinical trial failure risk: nintedanib DPI may not demonstrate adequate safety or efficacy in Phase 2
- Competition from approved oral nintedanib and other IPF therapies
- Regulatory and manufacturing risks for inhaled formulation
- No revenue from this program for several years if successful
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305858 |
Track record
17 reports on MNKD
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
- Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
- Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
- Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
- Jun 3, 202623w ago Press Release Neutral 5/10 Viewing Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
- Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
- May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers